复星医药14亿入局阿尔茨海默病,缘何选择押注绿谷“九期一”?

21财经
Dec 15, 2025

21世纪经济报道记者季媛媛 上海报道近日,阿尔茨海默病药物赛道异常热闹。在两款近年来最具突破性的阿尔茨海默病对因治疗药物——仑卡奈单抗注射液和多奈单抗注射液双双入选我国首版《商业健康保险创新药品目录》后,争议与机遇并存的国产阿尔茨海默病药物甘露特钠,在面临停产、换证危机之际,迎来了中国医药巨头复星医药的入局。12月15日,复星医药(600196.SH;02196.HK)宣布控股子公司复星医药产业与...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10